Alcoholic liver disease
||This article possibly contains original research. (July 2012)|
|Alcoholic liver disease|
|Classification and external resources|
Alcoholic liver disease is a term that encompasses the hepatic manifestations of alcohol overconsumption, including fatty liver, alcoholic hepatitis, and chronic hepatitis with hepatic fibrosis or cirrhosis.
It is the major cause of liver disease in Western countries. Although steatosis (fatty liver) will develop in any individual who consumes a large quantity of alcoholic beverages over a long period of time, this process is transient and reversible. Of all chronic heavy drinkers, only 15–20% develop hepatitis or cirrhosis, which can occur concomitantly or in succession.
How alcohol damages the liver is not completely understood. 80% of alcohol passes through the liver to be detoxified. Chronic consumption of alcohol results in the secretion of pro-inflammatory cytokines (TNF-alpha, Interleukin 6 [IL6] and Interleukin 8 [IL8]), oxidative stress, lipid peroxidation, and acetaldehyde toxicity. These factors cause inflammation, apoptosis and eventually fibrosis of liver cells. Why this occurs in only a few individuals is still unclear. Additionally, the liver has tremendous capacity to regenerate and even when 75% of hepatocytes are dead, it continues to function as normal.
- 1 Risk factors
- 2 Pathophysiology
- 3 Diagnosis
- 4 Treatment
- 5 Complications and prognosis
- 6 References
- 7 External links
The risk factors presently known are:
- Quantity of alcohol taken: Consumption of 60–80g per day (about 75–100 ml/day) for 20 years or more in men, or 20g/day (about 25 ml/day) for women significantly increases the risk of hepatitis and fibrosis by 7 to 47%,
- Pattern of drinking: Drinking outside of meal times increases up to 3 times the risk of alcoholic liver disease.
- Gender: Women are twice as susceptible to alcohol-related liver disease, and may develop alcoholic liver disease with shorter durations and doses of chronic consumption. The lesser amount of alcohol dehydrogenase secreted in the gut, higher proportion of body fat in women, and changes in fat absorption due to the menstrual cycle may explain this phenomenon.
- Hepatitis C infection: A concomitant hepatitis C infection significantly accelerates the process of liver injury.
- Genetic factors: Genetic factors predispose both to alcoholism and to alcoholic liver disease. Both monozygotic twins are more likely to be alcoholics and to develop liver cirrhosis than both dizygotic twins. Polymorphisms in the enzymes involved in the metabolism of alcohol, such as ADH, ALDH, CYP4502E1, mitochondrial dysfunction, and cytokine polymorphism may partly explain this genetic component. However, no specific polymorphisms have currently been firmly linked to alcoholic liver disease.
- Iron overload (Hemochromatosis)
- Diet: Malnutrition, particularly vitamin A and E deficiencies, can worsen alcohol-induced liver damage by preventing regeneration of hepatocytes. This is particularly a concern as alcoholics are usually malnourished because of a poor diet, anorexia, and encephalopathy.
Fatty change, or steatosis is the accumulation of fatty acids in liver cells. These can be seen as fatty globules under the microscope. Alcoholism causes development of large fatty globules (macro vesicular steatosis) throughout the liver and can begin to occur after a few days of heavy drinking. Alcohol is metabolized by alcohol dehydrogenase (ADH) into acetaldehyde, then further metabolized by aldehyde dehydrogenase (ALDH) into acetic acid, which is finally oxidized into carbon dioxide (CO2) and water ( H2O). This process generates NADH, and increases the NADH/NAD+ ratio. A higher NADH concentration induces fatty acid synthesis while a decreased NAD level results in decreased fatty acid oxidation. Subsequently, the higher levels of fatty acids signal the liver cells to compound it to glycerol to form triglycerides. These triglycerides accumulate, resulting in fatty liver.
Alcoholic hepatitis is characterized by the inflammation of hepatocytes. Between 10% and 35% of heavy drinkers develop alcoholic hepatitis (NIAAA, 1993). While development of hepatitis is not directly related to the dose of alcohol, some people seem more prone to this reaction than others. This is called alcoholic steato necrosis and the inflammation appears to predispose to liver fibrosis. Inflammatory cytokines (TNF-alpha, IL6 and IL8) are thought to be essential in the initiation and perpetuation of liver injury by inducing apoptosis and necrosis. One possible mechanism for the increased activity of TNF-α is the increased intestinal permeability due to liver disease. This facilitates the absorption of the gut-produced endotoxin into the portal circulation. The Kupffer cells of the liver then phagocytose endotoxin, stimulating the release of TNF-α. TNF-α then triggers apoptotic pathways through the activation of caspases, resulting in cell death.
Cirrhosis is a late stage of serious liver disease marked by inflammation (swelling), fibrosis (cellular hardening) and damaged membranes preventing detoxification of chemicals in the body, ending in scarring and necrosis (cell death). Between 10% to 20% of heavy drinkers will develop cirrhosis of the liver (NIAAA, 1993). Acetaldehyde may be responsible for alcohol-induced fibrosis by stimulating collagen deposition by hepatic stellate cells. The production of oxidants derived from NADPH oxi- dase and/or cytochrome P-450 2E1 and the formation of acetaldehyde-protein adducts damage the cell membrane. Symptoms include jaundice (yellowing), liver enlargement, and pain and tenderness from the structural changes in damaged liver architecture. Without total abstinence from alcohol use, will eventually lead to liver failure. Late complications of cirrhosis or liver failure include portal hypertension (high blood pressure in the portal vein due to the increased flow resistance through the damaged liver), coagulation disorders (due to impaired production of coagulation factors), ascites (heavy abdominal swelling due to buildup of fluids in the tissues) and other complications, including hepatic encephalopathy and the hepatorenal syndrome. Cirrhosis can also result from other causes than alcohol abuse, such as viral hepatitis and heavy exposure to toxins other than alcohol. The late stages of cirrhosis may look similar medically, regardless of cause. This phenomenon is termed the "final common pathway" for the disease. Fatty change and alcoholic hepatitis with abstinence can be reversible. The later stages of fibrosis and cirrhosis tend to be irreversible, but can usually be contained with abstinence for long periods of time.
In the early stages, patients with ALD exhibits subtle and often no abnormal physical findings. It is usually not until development of advanced liver disease that stigmata of chronic liver disease become apparent. Early ALD is usually discovered during routine health examinations when liver enzyme levels are found to be elevated. These usually reflect alcoholic hepatic steatosis. Microvesicular and macrovesicular steatosis with inflammation are seen in liver biopsy specimens. These histologic features of ALD are indistinguishable from those of nonalcoholic fatty liver disease. Steatosis usually resolves after discontinuation of alcohol use.Continuation of alcohol use will result in a higher risk of progression of liver disease and cirrhosis. In patients with acute alcoholic hepatitis,clinical manifestations include fever, jaundice, hepatomegaly, and possible hepatic decompensation with hepatic encephalopathy,variceal bleeding,and ascites accumulation.Tender hepatomegaly may be present, but abdominal pain is unusual. Occasionally, the patient may be asymptomatic.
In patients with alcoholic hepatitis, the serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio is greater than 2:1.AST and ALT levels are almost always less than 500. The elevated AST to ALT ratio is due to deficiency of pyridoxal-6-phosphate, which is required in the ALT enzyme synthetic pathway. Furthermore, alcohol metabolite–induced injury of hepatic mitochondria results in AST isoenzyme release. Other laboratory findings include red blood cell macrocytosis (mean corpuscular volume > 100) and elevations of serum γ-glutamyl transferase, alkaline phosphatase, and bilirubin levels. Folate level is reduced in alcoholic patients due to decreased intestinal absorption, increased bone marrow requirement for folate in the presence of alcohol,and increased urinary loss.The magnitude of leukocytosis reflects severity of liver injury. Histologic features include Mallory bodies, giant mitochondria, hepatocyte necrosis, and neutrophil infiltration at the perivenular area. Mallory bodies, which are also present in other liver diseases,are condensations of cytokeratin components in the hepatocyte cytoplasm and do not contribute to liver injury.Up to 70% of patients with moderate to severe alcoholic hepatitis already have cirrhosis identifiable on biopsy examination at the time of diagnosis.
Patients with chronic HCV infection should abstain from any alcohol intake, due to the risk for rapid acceleration of liver disease.
Alcohol-induced liver damage occurs via generation of oxidants. Thus alternative health care practitioners routinely recommend natural antioxidant supplements like milk thistle. Currently, there exists no substantive clinical evidence to suggest that milk thistle or other antioxidant supplements are efficacious beyond placebo in treating liver disease caused by chronic alcohol consumption. However S-adenosyl methionine has demonstrated hepatoprotective benefits in alcohol-induced liver injury in some of the studies.
When all else fails and the liver is severely damaged, the only alternative is a liver transplant. While this is a viable option, liver transplant donors are scarce and usually there is a long waiting list in any given hospital. One of the criteria to become eligible for a liver transplant is to discontinue alcohol consumption for a minimum of six months.
Standard fluid, mineral, and vitamin replacement and withdrawal precautions are mandatory for patients hospitalized with decompensated liver cirrhosis. Enteral as well as tube feeding has been found to be associated with decreased mortality. Continued enteral nutrition support after hospitalization also improves long-term morbidity. Dietary protein should not be restricted in alcoholic hepatitis for fear of hepatic encephalopathy.In the setting of hepatic encephalopathy,branched-chain amino acids (BCAAs) may be considered. Patients with liver cirrhosis usually have protein malnutrition with decreased BCAAs (leucine, isoleucine, and valine). A decrease in BCAA has been associated with serum hypoalbuminemia and elevated arterial ammonia levels.Recent formulations have resolved the poor taste by incorporation of BCAA into granules. Despite some small clinical studies suggesting benefit in improving metabolite profile and hepatic encephalopathy, there is still a lack of convincing evidence to justify the use of this expensive supplement to significantly improve morbidity and mortality. In patients with alcoholic hepatitis or fulminant hepatic failure, BCAA has not been found to influence short-term or long-term survival.
Thirteen randomized controlled trials have examined corticosteroid therapy in severe acute alcoholic hepatitis. Although five studies have shown benefit in survival,mostly in rural populations,the remaining studies have been equivocal. Significant improvement in liver function is evident at 7 days after initiation of therapy. Overall, corticosteroid therapy is beneficial in improving 30- and 60-day mortality only in patients with severe acute alcoholic hepatitis and an MDF greater than 32,in the absence of acute gastrointestinal bleeding, renal failure, acute infection, or pancreatitis. Twomonth survival with corticosteroid therapy is about 80%,but up to 40% of patients still die in 6 months. The benefit of corticosteroid therapy may be present up to 1 year. A recent study demonstrated the use of the Lille model in attempting to identify poor outcome at 6 months of follow-up inpatients with MDF of 32 or higher treated with either prednisolone (40 g/day orally) or methylprednisolone (32 mg/day intravenously) for 28 days. Patients with a score greater than 0.45 using the Lille model had a mortality rate of 76% at 6 months. This study suggests that alternative therapies should be considered in patients with scores above 0.45 after 1 week of treatment with steroids. Prednisolone may have a theoretical advantage over prednisone because it does not require hepatic metabolism for the active component.It is given at a dose of 40 mg daily for 4 weeks, followed by a rapid 4-week taper. Although use of corticosteroids in the treatment of ALD was recommended in a 1998 American College of Gastroenterology guideline, clinical use has been infrequent.
Anti–Tumor Necrosis Factor Therapy
TNF has been implicated in the pathogenesis of ALD, and elevated levels are found in patients with alcoholic hepatitis. Anti-TNF treatment prevents liver injury in a murine model of ALD, and this therapy has also been studied in humans. Pentoxyphylline, an inhibitor of TNF, at 400 mg orally three times per day, was shown to decrease the risk of hepatorenal syndrome in patients whose MDF is greater than 32. The 28-day mortality for the pentoxyphylline group was 24%, compared with 46% for the placebo group. Survival benefit was related to a reduction in mortality associated with the hepatorenal syndrome. The decrease in serum TNFα levels was not statistically significant when compared with placebo. Treatment with anti-TNF monoclonal antibody (infliximab, a chimeric mouse and human antibody that neutralizes soluble TNFα) and etanercept (a p75-soluble TNF receptor Fc fusion protein) has yet to reveal survival benefit in clinical trials for ALD, which are often inadequately sized and include some patients suffering fatal complications.
Although in rare cases liver cirrhosis is reversible,the disease process remains mostly irreversible. Liver transplantation remains the only definitive therapy.Today,survival after liver transplantation is similar for patients with ALD and nonALD. The requirements for transplant listing are the same as those for other types of liver disease, except for a 6-month sobriety prerequisite along with psychiatric evaluation and rehabilitation assistance (ie, Alcoholics Anonymous). Specific requirements vary among the transplant centers. Relapse to alcohol use after transplant listing results in delisting. Re-listing is possible in many institutions, but only after 3–6 months of sobriety. There are limited data on transplant survival in patients transplanted for acute alcoholic hepatitis,but it is believed to be similar to that in nonacute ALD, non-ALD, and alcoholic hepatitis with MDF less than 32.
Complications and prognosis
The prognosis for patients with ALD depends on the liver histology as well as cofactors, such as concomitant chronic viral hepatitis.Among patients with alcoholic hepatitis, progression to liver cirrhosis occurs at 10–20% per year, and 70% will eventually develop cirrhosis. Despite cessation of alcohol use, only 10% will have normalization of histology and serum liver enzyme levels. As previously noted, the MDF has been used to predict short-term mortality (ie, MDF ≥ 32 associated with spontaneous survival of 50–65% without corticosteroid therapy, and MDF < 32 associated with spontaneous survival of 90%).The Model for End-Stage Liver Disease (MELD) score has also been found to have similar predictive accuracy in 30day (MELD > 11) and 90-day (MELD > 21) mortality. Liver cirrhosis develops in 6–14% of those who consume more than 60–80 g of alcohol daily for men and more than 20 g daily for women. Even in those who drink more than 120 g daily, only 13.5% will suffer serious alcohol-related liver injury. Nevertheless, alcohol-related mortality was the third leading cause of death in 2003 in the United States. Worldwide mortality is estimated to be 150,000 per year.
- O'Shea RS, Dasarathy S, McCullough AJ (January 2010). "Alcoholic liver disease: AASLD Practice Guidelines" (PDF). Hepatology 51 (1): 307–28. doi:10.1002/hep.23258. PMID 20034030.
- Menon KV, Gores GJ, Shah VH (October 2001). "Pathogenesis, diagnosis, and treatment of alcoholic liver disease" (PDF). Mayo Clin. Proc. 76 (10): 1021–9. doi:10.4065/76.10.1021. PMID 11605686.
- Longstreth, George F.; Zieve, David (eds.) (18 October 2009). "Alcoholic Liver Disease". MedLinePlus: Trusted Health Information for You. Bethesda, MD: US National Library of Medicine & National Institutes of Health. Archived from the original on 22 January 2010. Retrieved 27 January 2010.
- Mandayam S, Jamal MM, Morgan TR (August 2004). "Epidemiology of alcoholic liver disease". Semin. Liver Dis. 24 (3): 217–32. doi:10.1055/s-2004-832936. PMID 15349801.
- Inaba, Darryl; Cohen, William B. (2004). Uppers, downers, all arounders: physical and mental effects of psychoactive drugs (5th ed.). Ashland, Or: CNS Publications. ISBN 0-926544-27-6.
- Inaba & Cohen 2004, p. 185
- McCullough, AJ; O'Connor, JF (November 1998). "Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology.". The American journal of gastroenterology 93 (11): 2022–36. doi:10.1111/j.1572-0241.1998.00587.x. PMID 9820369.
- Niemelä, O (February 2007). "Biomarkers in alcoholism.". Clinica chimica acta; international journal of clinical chemistry 377 (1-2): 39–49. doi:10.1016/j.cca.2006.08.035. PMID 17045579.
- Niemelä, O (February 2007). "Biomarkers in alcoholism.". Clinica chimica acta; international journal of clinical chemistry 377 (1-2): 39–49. doi:10.1016/j.cca.2006.08.035. PMID 17045579.
- Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H et al. (1989). "Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver". J Hepatol 9 (9): 105–113. doi:10.1016/0168-8278(89)90083-4.
- Rambaldi A, Jacobs BP, Iaquinto G, Gluud C (November 2005). "Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials". Am. J. Gastroenterol. 100 (11): 2583–91. doi:10.1111/j.1572-0241.2005.00262.x. PMID 16279916.
- Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C (2011). Bjelakovic, Goran, ed. "Antioxidant supplements for liver diseases". Cochrane Database Syst Rev (3): CD007749. doi:10.1002/14651858.CD007749.pub2. PMID 21412909.
- Arthur I Cederbaum, Department of Pharmacology and Systems Therapeutics, Box 1603, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, NY 10029, United States (March 2010). [http://www.wjgnet.com/1007-9327/full/ v16/i11/1366.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i11. 1366 "Hepatoprotective effects of S -adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury"]. World J Gastroenterol 16 (11): 1366–1376. doi:10.3748/wjg.v16.i11.1366.
- "Alcoholic Liver Disease: Introduction". Johns Hopkins Medicine: Gastroenterology & Hepatology. Baltimore, MD: Johns Hopkins Hospital. 2010. Retrieved 27 January 2010.
- Gyhra, A; Pierart, J; Torres, P; Prieto, L (July 1992). "Experimental cardiac tamponade with a myocardial wound: the effect of rapid intravenous infusion of saline.". The Journal of trauma 33 (1): 25–8. doi:10.1097/00005373-199207000-00006. PMID 1635102.
- Maddrey, WC; Boitnott, JK; Bedine, MS; Weber FL, Jr; Mezey, E; White RI, Jr (August 1978). "Corticosteroid therapy of alcoholic hepatitis.". Gastroenterology 75 (2): 193–9. PMID 352788.
- Mathurin, P (September 2005). "Corticosteroids for alcoholic hepatitis--what's next?". Journal of hepatology 43 (3): 526–33. doi:10.1016/j.jhep.2005.06.003. PMID 16026887.
- Naveau, S; Chollet-Martin, S; Dharancy, S; Mathurin, P; Jouet, P; Piquet, MA; Davion, T; Oberti, F; Broët, P; Emilie, D; Foie-Alcool group of the Association Française pour l'Etude du, Foie (May 2004). "A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.". Hepatology (Baltimore, Md.) 39 (5): 1390–7. doi:10.1002/hep.20206. PMID 15122768.
- Neuberger, J; Schulz, KH; Day, C; Fleig, W; Berlakovich, GA; Berenguer, M; Pageaux, GP; Lucey, M; Horsmans, Y; Burroughs, A; Hockerstedt, K (January 2002). "Transplantation for alcoholic liver disease.". Journal of hepatology 36 (1): 130–7. doi:10.1016/s0168-8278(01)00278-1. PMID 11804676.
- Dunn, W; Jamil, LH; Brown, LS; Wiesner, RH; Kim, WR; Menon, KV; Malinchoc, M; Kamath, PS; Shah, V (February 2005). "MELD accurately predicts mortality in patients with alcoholic hepatitis.". Hepatology (Baltimore, Md.) 41 (2): 353–8. doi:10.1002/hep.20503. PMID 15660383.
- Sheth, M; Riggs, M; Patel, T (2002). "Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis.". BMC gastroenterology 2 (1): 2. doi:10.1186/1471-230X-2-2. PMC 65516. PMID 11835693.
- Morphology of Alcoholic Liver Disease | Medchrome
- "Alcoholic liver disease (per capita) (most recent) by country". NationMaster. Archived from the original on 21 June 2009. Retrieved 29 July 2009.